Table 2 Patient characteristics for the total study cohort
Variables | Volatile/inhalational (n = 464) | IV (n = 530) | P-value |
|---|---|---|---|
Breast | 0.693 | ||
Left | 230 (49.5) | 268 (50.6) | |
Right | 230 (49.5) | 254 (47.9) | |
Missing | 4 (0.1) | 8 (1.5) | |
Axillary management | 0.009 | ||
ALND | 160 (34.5) | 182 (33.7) | |
SLNB | 205 (44.2) | 224 (42.3) | |
SLNB and ALND | 82 (17.7) | 109 (20.4) | |
Missing | 17 (3.6) | 15 (3.1) | |
Type of tumor | 0.412 | ||
Invasive ductal carcinoma | 458 (98.7) | 517 (97.5) | |
Other types | 6 (1.3) | 13 (2.5) | |
Tumor size | 0.237 | ||
(< 2) | 103 (22.2) | 137 (25.8) | |
(2–5) | 318 (68.5) | 329 (62.2) | |
(> 5) | 21 (4.5) | 24 (4.5) | |
Missing | 22 (4.8) | 40 (7.5) | |
Tumor grade | 0.864 | ||
I | 117 (25.3) | 123 (23.2) | |
II | 215 (46.3) | 245 (46.2) | |
III | 100 (21.5) | 109 (20.6) | |
Missing | 32 (6.9) | 53 (10.0) | |
Nuclear grade | 0.063 | ||
I | 117 (25.3) | 123 (23.2) | |
II | 215 (46.3) | 245 (46.2) | |
III | 100 (21.5) | 109 (20.6) | |
Missing | 32 (6.9) | 53 (10.0) | |
Multifocal | 0.001 | ||
No | 462 (99.5) | 513 (96.8) | |
Yes | 2 (0.5) | 17 (3.2) | |
In situ component | 0.103 | ||
No | 178 (38.4) | 239 (45.1) | |
Yes | 286 (61.6) | 291 (54.9) | |
Tumor necrosis | 0.213 | ||
No | 253 (54.5) | 300 (56.6) | |
Yes | 211 (45.5) | 230 (43.4) | |
Type of lymph node involvement | 0.229 | ||
Vascular | 122 (26.3) | 130 (24.5) | |
Pre-neural | 39 (8.4) | 29 (5.5) | |
None | 216 (46.5) | 245 (46.2) | |
Vascular/ pre-neural | 49 (10.6) | 65 (12.3) | |
Missing | 38 (8.2) | 61 (11.5) | |
Margin | 0.254 | ||
Free | 462 (99.5) | 526 (99.2) | |
Positive | 2 (0.5) | 4 (0.8) | |
ER | 0.009 | ||
No | 84 (18.1) | 108 (20.4) | |
Yes | 366 (78.9) | 382 (72.1) | |
Missing | 14 (3.0) | 40 (7.5) | |
PR | 0.006 | ||
No | 104 (22.5) | 131 (24.7) | |
Yes | 345 (74.3) | 356 (67.2) | |
Missing | 15 (3.2) | 43 (8.1) | |
Her2 | 0.63 | ||
No | 296 (63.8) | 360 (68.0) | |
Yes | 97 (20.9) | 92 (17.3) | |
Missing | 71 (15.3) | 78 (14.7) | |
Neoadjuvant chemotherapy | 0.392 | ||
No | 444 (95.7) | 503 (94.9) | |
Yes | 20 (4.3) | 27 (5.1) | |
Adjuvant chemotherapy | 0.401 | ||
No | 44 (9.5) | 43 (8.1) | |
Yes | 420 (90.5) | 487 (91.9) | |
Radiotherapy | 0.253 | ||
No | 73 (15.7) | 100 (18.9) | |
Yes | 391 (84.3) | 430 (81.1) | |
IORT | 0.042 | ||
No | 438 (94.3) | 482 (90.9) | |
Yes | 26 (5.7) | 48 (9.1) | |
Hormone therapy | 0.220 | ||
No | 108 (23.3) | 150 (28.3) | |
Yes | 357 (76.7) | 380 (71.7) | |
Recurrence | 0.958 | ||
No | 387 (83.4) | 444 (83.8) | |
Yes | 66 (14.2) | 75 (14.1) | |
Missing | 11 (2.4) | 11 (2.1) | |
Survival | 0.669 | ||
Live | 409 (88.2) | 473 (89.3) | |
Dead | 41 (8.8) | 43 (8.1) | |
Missing | 14 (3.0) | 14 (2.6) |